He is President and spokesperson for G5 santé, a lobbying group for French pharmaceutical companies, including BioMérieux, Guerbet, Ipsen, the Laboratoire français du Fractionnement et des Biotechnologies, Laboratoires Pierre Fabre, Sanofi, Stallergenes and Laboratoires Théa.
In 2010, Stallergenes signed an exclusive partnership agreement with Japanese biopharmaceutical company Shionogi & Co., Ltd. to promote the development, registration, and distribution of the "Stalair Program" in Japan.